- Home
- NLOP vs ITOS Comparison
NLOP vs ITOS Comparison
Compare NLOP & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLOP
- ITOS
- Stock Information
- Founded
- NLOP N/A
- ITOS 2011
- Country
- NLOP United States
- ITOS United States
- Employees
- NLOP N/A
- ITOS N/A
- Industry
- NLOP
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NLOP
- ITOS Health Care
- Exchange
- NLOP Nasdaq
- ITOS Nasdaq
- Market Cap
- NLOP 498.8M
- ITOS 450.9M
- IPO Year
- NLOP N/A
- ITOS 2020
- Fundamental
- Price
- NLOP $29.11
- ITOS N/A
- Analyst Decision
- NLOP Strong Buy
- ITOS Hold
- Analyst Count
- NLOP 1
- ITOS 6
- Target Price
- NLOP $46.00
- ITOS $10.40
- AVG Volume (30 Days)
- NLOP 146.7K
- ITOS 1.6M
- Earning Date
- NLOP 08-06-2025
- ITOS 08-06-2025
- Dividend Yield
- NLOP 10.65%
- ITOS N/A
- EPS Growth
- NLOP N/A
- ITOS N/A
- EPS
- NLOP N/A
- ITOS N/A
- Revenue
- NLOP $117,598,000.00
- ITOS N/A
- Revenue This Year
- NLOP N/A
- ITOS N/A
- Revenue Next Year
- NLOP N/A
- ITOS N/A
- P/E Ratio
- NLOP N/A
- ITOS N/A
- Revenue Growth
- NLOP N/A
- ITOS 177.89
- 52 Week Low
- NLOP $26.10
- ITOS $4.80
- 52 Week High
- NLOP $34.53
- ITOS $17.63
- Technical
- Relative Strength Index (RSI)
- NLOP 29.76
- ITOS 1.63
- Support Level
- NLOP $29.02
- ITOS $10.10
- Resistance Level
- NLOP $29.36
- ITOS $10.17
- Average True Range (ATR)
- NLOP 0.46
- ITOS 0.02
- MACD
- NLOP 0.03
- ITOS -0.80
- Stochastic Oscillator
- NLOP 13.40
- ITOS 0.00
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.